Jaime Abrego
Overview
Explore the profile of Jaime Abrego including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
769
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abrego J, Sanford-Crane H, Oon C, Xiao X, Betts C, Sun D, et al.
Cancer Discov
. 2022 Jul;
12(10):2414-2433.
PMID: 35894778
Significance: Prior studies demonstrate the important moonlighting functions of metabolic enzymes in cancer. We find that the mitochondrial transaminase GOT2 binds directly to fatty acid ligands that regulate the nuclear...
2.
King R, Shukla S, He C, Vernucci E, Thakur R, Attri K, et al.
Oncogene
. 2022 Jan;
41(7):971-982.
PMID: 35001076
Metabolic alterations regulate cancer aggressiveness and immune responses. Given the poor response of pancreatic ductal adenocarcinoma (PDAC) to conventional immunotherapies, we investigated the link between metabolic alterations and immunosuppression. Our...
3.
Mulder S, Dasgupta A, King R, Abrego J, Attri K, Murthy D, et al.
Cancer Lett
. 2020 Aug;
491:70-77.
PMID: 32735910
Cancer cachexia patients experience significant muscle wasting, which impairs the quality of life and treatment efficacy for patients. Skeletal muscle protein turnover is imparted by increased expression of ubiquitin-proteasome pathway...
4.
Dasgupta A, Shukla S, Vernucci E, King R, Abrego J, Mulder S, et al.
J Exp Med
. 2020 May;
217(7).
PMID: 32441762
Approximately one third of cancer patients die due to complexities related to cachexia. However, the mechanisms of cachexia and the potential therapeutic interventions remain poorly studied. We observed a significant...
5.
Vernucci E, Abrego J, Gunda V, Shukla S, Dasgupta A, Rai V, et al.
Cancers (Basel)
. 2019 Dec;
12(1).
PMID: 31861288
Pancreatic cancer is the third leading cause of cancer-related deaths in the USA. Pancreatic tumors are characterized by enhanced glycolytic metabolism promoted by a hypoxic tumor microenvironment and a resultant...
6.
Sanford-Crane H, Abrego J, Sherman M
Cancers (Basel)
. 2019 May;
11(5).
PMID: 31058816
Fibroblast activation is an accompanying feature of solid tumor progression, resembling a conserved host response to tissue damage. Cancer-associated fibroblasts (CAFs) comprise a heterogeneous and plastic population with increasingly appreciated...
7.
Murthy D, Vernucci E, Goode G, Abrego J, Singh P
Methods Mol Biol
. 2018 Jan;
1742:81-93.
PMID: 29330792
Hypoxia is frequently observed in human cancers and induces global metabolic reprogramming that includes an increase in glucose uptake and glycolysis, alterations in NAD(P)H/NAD(P) and intracellular ATP levels, and increased...
8.
Shukla S, Purohit V, Mehla K, Gunda V, Chaika N, Vernucci E, et al.
Cancer Cell
. 2017 Sep;
32(3):392.
PMID: 28898700
No abstract available.
9.
Tadros S, Shukla S, King R, Gunda V, Vernucci E, Abrego J, et al.
Cancer Res
. 2017 Aug;
77(20):5503-5517.
PMID: 28811332
Pancreatic adenocarcinoma is moderately responsive to gemcitabine-based chemotherapy, the most widely used single-agent therapy for pancreatic cancer. Although the prognosis in pancreatic cancer remains grim in part due to poor...
10.
Gebregiworgis T, Purohit V, Shukla S, Tadros S, Chaika N, Abrego J, et al.
J Proteome Res
. 2017 Aug;
16(10):3536-3546.
PMID: 28809118
Pancreatic cancer cells overexpressing Mucin 1 (MUC1) rely on aerobic glycolysis and, correspondingly, are dependent on glucose for survival. Our NMR metabolomics comparative analysis of control (S2-013.Neo) and MUC1-overexpressing (S2-013.MUC1)...